Pitavastatin (usually as a calcium salt) is a member of the blood cholesterol lowering medication class of statins.
Pitavastatin is an inhibitor of HMG-CoA reductase, the enzyme that catalyses the first step of cholesterol synthesis.
It was patented in 1987 and approved for medical use in 2003. It is available in Japan, South Korea and in India. In the US, it received FDA approval in 2009.
Kowa Pharmaceuticals, a subsidiary of Kowa Company, is the owner of the American patent to pitavastatin. |
Read full article at Wikipedia
|
InChI=1S/C23H20F3N5O2S2/c1- 23(2,3) 21- 30- 18(19(34- 21) 16- 10- 11- 28- 22(27) 29- 16) 12- 6- 4- 9- 15(17(12) 26) 31- 35(32,33) 20- 13(24) 7- 5- 8- 14(20) 25/h4- 11,31H,1- 3H3,(H2,27,28,29) |
BFSMGDJOXZAERB-UHFFFAOYSA-N |
CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(s1)-c1ccnc(N)n1 |
|
Bronsted base
A molecular entity capable of accepting a hydron from a donor (Bronsted acid).
(via organic amino compound )
|
|
anticoronaviral agent
Any antiviral agent which inhibits the activity of coronaviruses.
B-Raf inhibitor
A serine/threonine kinase inhibitor that specifically inhibits human mutant serine/threonine kinase (B-Raf)
|
|
antineoplastic agent
A substance that inhibits or prevents the proliferation of neoplasms.
|
|
View more via ChEBI Ontology
N- {3- [5- (2- aminopyrimidin- 4- yl)- 2- tert- butyl- 1,3- thiazol- 4- yl]- 2- fluorophenyl}- 2,6- difluorobenzenesulfonamide
|
1195765-45-7
|
CAS Registry Number
|
ChemIDplus
|
19689971
|
Reaxys Registry Number
|
Reaxys
|
|